✦ LIBER ✦

NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma

✍ Scribed by Christian Griffiths; Nicola Hay; Frances Sutcliffe; Andrew Stevens

Book ID: 117785599
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 213 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70042-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pazopanib for the First-Line Treatment o

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

✍ Kilonzo, Mary; Hislop, Jenni; Elders, Andrew; Fraser, Cynthia; Bissett, Donald; 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 280 KB

Budget impact analysis of first-line tre

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

✍ Villa, Guillermo; Hernández-Pastor, Luis-Javier 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 244 KB

Pazopanib for the Treatment of Metastati

Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma

✍ Amy M. Pick; Kelly K. Nystrom 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 357 KB

Cost-Effectiveness of Temsirolimus for F

Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

✍ Martin Hoyle; Colin Green; Jo Thompson-Coon; Zulian Liu; Karen Welch; Tiffany Mo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Cost-Effectiveness of Pazopanib as First

Cost-Effectiveness of Pazopanib as First Line Treatment for Metastatic Renal Cell Carcinoma in Brazil: Updated Analysis

✍ Pepe, C.; Sedlmayer, C.; Machado, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

NICE guidance on bortezomib and thalidom

NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma

✍ Sally Doss; Nicola Hay; Frances Sutcliffe 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 48 KB